Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Observational 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 6Waldenstrom Macroglobulinemia 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Lymphocytic, Chronic, B-Cell 2Intraocular Lymphoma 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms, Male 2Wilms Tumor 1Unspecified Childhood Solid Tumor, Protocol Specific 1Thromboembolism 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Abnormalities 1Sezary Syndrome 1Rectal Neoplasms 1Radiation Injuries 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Ipilimumab 114pembrolizumab 95Nivolumab 91aldesleukin 86Interleukin-2 57Cyclophosphamide 54Dacarbazine 52Vemurafenib 39trametinib 37Temozolomide 37incomplete Freund's adjuvant 35fludarabine phosphate 35sargramostim 32dabrafenib 32fludarabine 26Bevacizumab 26Paclitaxel 22MART-1 Antigen 21Granulocyte-Macrophage Colony-Stimulating Factor 21montanide ISA 51 20Interferon-alpha 20Cisplatin 20Carboplatin 19Sorafenib 18Introns 17Biopsy 17cobimetinib 16Radiosurgery 16atezolizumab 15Radiotherapy 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Melanoma × Enzyme-Linked Immunosorbent Assay × Clear all
NCT01489423 2017-05-17

Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim

Eastern Cooperative Oncology Group

Completed
270 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡